MDS-175: Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial
Year: 2020
Type: conference-abstract
Authors: Uwe Platzbecker, Pierre Fenaux, Ghulam J. Mufti, Guillermo Garcia-Manero, Rami S. Komrokji, Rena Buckstein, María Diez-Campelo, Carlo Finelli, Mikkael A. Sekeres, Dominik Selleslag, Amy E. DeZern, Bruno Quesnel, Odile Beyne-Rauzy, Maria Teresa Voso, Peter L. Greenberg, Amer M. Zeidan, Lionel Adès, Amit Verma, Michael R. Savona, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Jessica Morison, Chrystal Louis, Peter G. Linde, Valeria Santini
Institutions: University Hospital Leipzig, Hôpital Saint-Louis, Université Paris Diderot, King's College London, The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Sunnybrook Health Science Centre, Sunnybrook Hospital, Odette Cancer Centre, Universidad de Salamanca, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Cleveland Clinic, AZ Sint-Jan, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Institut universitaire du cancer de Toulouse Oncopole, University of Rome Tor Vergata, Stanford University, Yale Cancer Center, Yale University, Albert Einstein College of Medicine, Montefiore Medical Center, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Bristol-Myers Squibb (United States), Acceleron Pharma (United States), Azienda Ospedaliero-Universitaria Careggi, University of Florence
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3110873099